Background {#Sec1}
==========

Approximately 25--35 % of patients develop biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically localized prostate cancer (PC) \[[@CR1], [@CR2]\]. Although salvage radiotherapy (SRT) is a standard treatment option for post-RP BCR \[[@CR3]--[@CR5]\], there is currently no consensus regarding its optimal timing. There are several commonly used definitions of BCR; most involve single or multiple prostate-specific antigen (PSA) values of at least ≥0.2 \[[@CR6]\], including the current official definition in Japan of two consecutive PSA values ≥0.2 ng/mL \[[@CR7]\]. To the best of our knowledge, the value of SRT delivered before meeting these definitions has not been investigated to date. We previously reported that salvage androgen deprivation therapy (ADT) administered before meeting the Japanese definition, referred to as "ultra-early salvage ADT", achieved a better oncological outcome than ADT administered after patients met the definition in pT2-4 N0 PC \[[@CR8]\].

On the other hand, several recent studies have suggested that SRT should be started before PSA levels reach 0.5 ng/mL \[[@CR9]--[@CR13]\]. Notably, Briganti et al. demonstrated that early SRT (eSRT; given at pre-radiation PSA ≤0.5 ng/mL) achieved an oncological outcome equivalent to adjuvant radiotherapy in patients with pT3N0 PC \[[@CR10]\].

In this context, the present study aimed to investigate the benefit of SRT given before patients meet a currently used definition \[[@CR7]\] (i.e. ultra-early SRT; ueSRT), by comparing the outcomes of patients treated with SRT at different timings after RP.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This retrospective analysis was approved by the internal institutional review board of Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (approval number: 3124). We reviewed 96 patients who underwent SRT after RP at our institution between 2006 and 2014. Of them, 19 patients who received ADT (neoadjuvant and/or adjuvant: 13; salvage: 6) prior to SRT and a patient who underwent SRT for pN1 disease were excluded. Finally, we retrospectively reviewed 76 patients with pT2-3N0M0 PC who underwent SRT after RP at our institution during this period. Of the 76 patients, 20 (26 %) received ueSRT for increasing PSA but before they met a current definition of BCR (two consecutive PSA values ≥0.2 ng/mL \[[@CR7]\]); 40 (53 %) received eSRT after meeting the definition but before PSA reached 0.5 ng/mL; and 16 (21 %) received delayed SRT (dSRT) after PSA reached 0.5 ng/mL. All 20 patients in the ueSRT group had at least one detectable PSA value, although they did not meet the above definition of BCR: In more details, 18 of 20 (90 %) patients started SRT before PSA values reached 0.2 ng/mL; and the remaining 2 (10 %) did it over only a single PSA value of 0.2 ng/mL. PSA doubling time was calculated in patients who had at least three PSA measurements after BCR but before initiating SRT, using all PSA measurements. The calculation assumed first-order kinetics, dividing the natural logarithm of 2 by the slope of the log PSA vs time of PSA measurements for each patient (in months) \[[@CR14]\].

Treatments {#Sec4}
----------

The most common surgical procedure of open RP with bilateral obturator lymph node dissection was performed in 59 (78 %) patients. Laparoscopic RP and robot-assisted laparoscopic RP were performed in six (8 %) and 11 (14 %) patients, respectively.

The standard technique for SRT was 3-dimensional conformal radiation therapy (3DCRT) in 61 (80 %) patients, while 15 (20 %) patients were treated with intensity-modulated radiotherapy (IMRT) to cover the prostate bed with reference to preoperative computed tomography and/or magnetic resonance imaging (Table [1](#Tab1){ref-type="table"}). The most common delivered dose was 66 Gy, though a few (6 of 76 \[8 %\]) patients received 70 Gy by IMRT with a simultaneous integrated boost to suspicious recurrent lesions detected by multi-parametric magnetic resonance imaging in addition to 66 Gy to the prostate bed, as per our ongoing prospective study (UMIN000009823: Dynamic contrast-enhanced magnetic resonance imaging study for biochemical failures after radical prostatectomy). All SRT regimens were given in 1.8--2.0-Gy daily fractions. For pre-radiation studies, computed tomography was used in most patients, whereas six (8 %) who participated in the prospective study mentioned above underwent 3-tesla dynamic contrast enhanced magnetic resonance imaging.Table 1Patient characteristicsParameterTotal (*n* = 76)ueSRT (*n* = 20)eSRT (*n* = 40)dSRT (*n* = 16)*P*Age at surgery, years, median (IQR)65 (61--69)68 (61--72)65 (61--69)64 (57--67)0.0574^a^Initial PSA, ng/mL, median (IQR)8.7 (6.4--12.6)9.2 (6.9--12.6)8.4 (5.9--13.0)9.3 (7.2--12.9)0.6684^a^Pathological T stage, no. (%): T237 (49)9 (45)21 (53)7 (44)0.0834^b^ T3a35 (46)10 (50)19 (48)6 (38) T3b4 (5)1 (5)0 (0)3 (19)Pathological GS, no. (%): ≤612 (16)3 (15)6 (15)3 (19)0.1533^b^ 749 (64)16 (80)26 (65)7 (44) ≥815 (20)1 (5)8 (20)6 (38) Gleason pattern 5 (including tertiary 5)27 (36)5 (25)14 (35)8 (50)0.2959^b^Extraprostatic extension, no. (%)37 (49)10 (50)18 (45)9 (56)0.7416^b^Lymphovascular invasion, no. (%)21 (28)3 (15)10 (25)8 (50)0.0568^b^Positive surgical margin, no. (%)57 (75)17 (85)28 (70)12 (75)0.4493^b^Seminal vesicle invasion, no. (%)4 (5)1 (5)0 (0)3 (19)0.0178\*^b^Perineural invasion, no. (%)58 (76)17 (85)28 (70)13 (81)0.3805^b^SRT technique, no. (%): 3DCRT61 (80)19 (95)27 (68)15 (94)0.0130\*^b^ IMRT15 (20)1 (5)13 (33)1 (6)Total dose, no. (%): 60--65 Gy10 (13)3 (15)5 (13)2 (13)0.9646^b^ 66 Gy60 (79)16 (80)31 (78)13 (81) 70 Gy6 (8)1 (5)4 (10)1 (6)Concomitant ADT, no. (%)12 (16)5 (25)2 (5)5 (31)0.0218\*^b^PSA doubling time, months, median (IQR)8.4 (4.6--20.1)--†12.7 (6.2--25.1)5.9 (3.5--14.3)--Median follow-up, months (IQR)70 (48--95)74 (57--99)73 (43--83)58 (41--99)0.5386^a^*SRT* salvage radiotherapy, *ueSRT* ultra-early salvage radiotherapy, *eSRT* early salvage radiotherapy, *dSRT* delayed salvage radiotherapy, *IQR* interquartile range, *PSA* prostate-specific antigen, *GS* Gleason score, *3DCRT* 3-dimensional conformal radiation therapy, *IMRT* intensity-modulated radiotherapy, *ADT* androgen deprivation therapy\*Statistically significant; ^a^one-way ANOVA; ^b^Pearson's χ^2^ test†In the ueSRT group, PSA doubling time was only calculable in two patients (3.9 and 5.6 months)

Endpoints and statistical analysis {#Sec5}
----------------------------------

The primary endpoint was failure of SRT, defined as a PSA value ≥0.2 ng/mL after PSA nadir following SRT \[[@CR9]\]. Secondary endpoints were clinical metastasis and cancer-specific mortality. Associations of various clinicopathological factors, including timing of SRT, with failure-free survival were assessed. Survival time was defined as the time (months) between RP and failure of SRT or last follow-up \[[@CR10]\]. The log-rank test and Cox proportional hazards model were used for univariate and multivariate analyses, respectively. All statistical analyses were performed using JMP Pro version 11.0.0 (SAS Institute, Cary, NC, USA). A value of *P* \< 0.05 was considered significant. Follow-up information was obtained as of August 2015.

Results {#Sec6}
=======

The patient characteristics of the whole population (*n* = 76) and according to the timing of SRT are summarized in Table [1](#Tab1){ref-type="table"}. During the follow-up period (median: 70 months; interquartile range: 48--95 months), four of 20 (20 %), nine of 40 (23 %) and seven of 16 (44 %) patients developed failure of SRT in the ueSRT, eSRT and dSRT groups, respectively. The outcome of dSRT was significantly worse than the others (log-rank test: *P* = 0.0424 for ueSRT; *P* = 0.0333 for eSRT), while there was no significant difference between ueSRT and eSRT (*P* = 0.6171, Fig. [1](#Fig1){ref-type="fig"}). Furthermore, there was a stronger outcome difference when comparing ueSRT + eSRT and dSRT (*P* = 0.0108, Fig. [2](#Fig2){ref-type="fig"}), whereas no significant difference was observed when comparing ueSRT and eSRT + dSRT (*P* = 0.2991, Fig. [3](#Fig3){ref-type="fig"}).Fig. 1Kaplan--Meier curves depicting failure-free survival according to three timings of SRT (log-rank test: *P* = 0.0364)Fig. 2Kaplan--Meier curves depicting failure-free survival of ueSRT + eSRT vs dSRT (log-rank test: *P* = 0.0108)Fig. 3Kaplan--Meier curves depicting failure-free survival of ueSRT vs eSRT + dSRT (log-rank test: *P* = 0.2991)

Univariate analysis revealed that the presence of Gleason pattern 5 (including tertiary pattern 5), lymphovascular invasion, perineural invasion, timing of SRT (ueSRT vs eSRT vs dSRT; and ueSRT + eSRT vs dSRT) and PSA doubling time \<6 months were associated with poorer failure-free survival (Table [2](#Tab2){ref-type="table"}). Of the two covariates regarding the timing of SRT, we only included "ueSRT + eSRT and dSRT" (a stronger one) but not "ueSRT vs eSRT vs dSRT" (a weaker one) in the subsequent multivariate model, because these factors should be closely-correlated and would therefore cancel out each other's statistical significance (i.e. multicollinearity). PSA doubling time was also excluded from the model, since it was only calculable in 51 (67 %) patients. Accordingly, multivariate analysis identified the presence of Gleason pattern 5, perineural invasion and dSRT (reference: ueSRT + eSRT) as independent predictors of failure of SRT (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate analyses of clinicopathological factors for failure-free survivalParameterCutoffUnivariateMultivariate*P*HR (95 % CI)*P*Age≥65 years vs \<65 years†0.2151Initial PSA≥20 ng/mL vs \<20 ng/mL0.9923Pathological T stage≥T3 vs ≤ T20.5521Pathological GS≥8 vs ≤70.0558Gleason pattern 5Yes vs no0.0004\*4.166 (1.351 to 12.76)0.0133\*Extraprostatic extensionYes vs no0.4370Lymphovascular invasionYes vs no0.0101\*1.005 (0.323 to 3.130)0.9935Positive surgical marginYes vs no0.2967Seminal vesicle invasionYes vs no0.1506Perineural invasionYes vs no0.0157\*5.876 (1.139 to 107.5)0.0316\*Timing of SRTueSRT vs eSRT vs dSRT0.0364\*----‡ueSRT + eSRT vs dSRT0.0108\*3.117 (1.141 to 7.880)0.0280\*ueSRT vs eSRT + dSRT0.2991SRT technique3DCRT vs IMRT0.4964Total dose≥66 Gy vs \<66 Gy0.6278Concomitant ADTYes vs no0.3118PSA doubling time≥6 months vs \<6 months0.0071\*----‡*HR* hazard ratio, *CI* confidence interval, *PSA* prostate-specific antigen, *GS* Gleason score, *SRT* salvage radiotherapy, *ueSRT* ultra-early salvage radiotherapy, *eSRT* early salvage radiotherapy, *dSRT* delayed salvage radiotherapy, *3DCRT* 3-dimensional conformal radiation therapy, *IMRT* intensity-modulated radiotherapy, *ADT* androgen deprivation therapy†median; \*statistically significant; ‡these covariates were excluded from the multivariate analysis (see text)

Concerning the treatment modality, although univariate analysis did not demonstrate a significant difference between 3DCRT vs IMRT, IMRT exhibited a non-significant trend for better failure-free survival than 3DCRT: 2 of 15 (13 %) patients who underwent IMRT failed biochemically, whereas 18 of 61 (30 %) who received 3DCRT did.

With regard to the secondary endpoints, two patients (3 %) in the dSRT group developed clinical metastases: One developed a solitary metastasis to a right iliac lymph node but has achieved undetectable PSA with subsequent salvage ADT; and another developed multiple metastases to bone and para-aortic lymph nodes and finally died of PC. No other patient than the latter one died from any cause during the follow-up period.

Discussion {#Sec7}
==========

The present study compared outcomes of different timings of SRT for post-RP BCR, especially focusing on the prognostic significance of ueSRT. During the follow-up period (median: 70 months), four of 20 (20 %), nine of 40 (23 %) and seven of 16 (44 %) patients failed biochemically in the ueSRT, eSRT and dSRT groups. No survival benefit of ueSRT compared to eSRT was demonstrated in the study, whereas dSRT was associated with worse prognosis as previously reported. These results thus support the current recommendations that SRT should be performed after two consecutive PSA values ≥0.2 ng/mL and before reaching 0.5 ng/mL \[[@CR9]--[@CR13]\].

To the best of our knowledge, no previous study has investigated the effects of SRT given before patients meet the current definition of BCR. Although we previously demonstrated the benefit of ultra-early salvage ADT for post-RP BCR in pT2-4 N0 patients \[[@CR8]\], this result was not reproducible for ueSRT. This difference may be attributable to the difference between systemic ADT and local radiation therapies, though the reason currently remains unclear.

Several studies have associated SRT given at a pre-radiation PSA ≤0.5 ng/mL with better outcomes \[[@CR9]--[@CR13]\], although current guidelines only recommend a pre-radiation PSA \<1.0 ng/mL \[[@CR3], [@CR4]\]. For example, Briganti et al. demonstrated that eSRT given before PSA reached 0.5 ng/mL achieved an equivalent oncological outcome to adjuvant radiotherapy in patients with pT3N0 PC, as stated above \[[@CR10]\]. Several clinical trials comparing the outcomes of adjuvant radiotherapy and eSRT are now underway to clarify this issue (RAVES; EORTC 22043-30041; GETUG-17) \[[@CR11], [@CR15]\].

Pathological Gleason pattern 5, including tertiary pattern 5, was an independent predictor of failure-free survival in this study. Some previous studies also reported that Gleason pattern 5 was a strong prognostic factor in patients undergoing salvage treatments (SRT and/or ADT) for post-RP BCR \[[@CR16], [@CR17]\]. Gleason pattern 5 may thus be a more critical marker than conventional Gleason grading system in this setting.

Perineural invasion was also identified as an independent predictor of failure-free survival. Several studies have reported perineural invasion as a significant prognostic factor in the setting of SRT for post-RP BCR \[[@CR18]--[@CR21]\]. Our results are in complete accord with these previous studies.

With regard to the treatment modality, although univariate analysis did not demonstrate a significant difference between 3DCRT vs IMRT, those who underwent IMRT (*n* = 15) had a relatively favorable outcome: Only 2 of 15 (13 %) patients failed biochemically. As new technologies such as IMRT and/or image-guided radiotherapy have improved outcomes of external beam radiotherapy \[[@CR22]\], its evaluations should be updated often.

Our study had several limitations. The ueSRT group may have included patients without evidence of BCR, which may have resulted in overestimation of the outcomes of ueSRT. Other limitations were its retrospective design, small sample size, selection bias and lead-time bias. Randomized prospective studies with longer follow-up periods are thus needed to confirm these preliminary results.

Conclusions {#Sec8}
===========

No survival benefit of ueSRT was shown in patients with post-RP BCR, whereas dSRT was associated with poorer outcome as reported in previous studies. These results may validate the current recommendations that SRT should be performed after two consecutive PSA values ≥0.2 ng/mL and before reaching 0.5 ng/mL.
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